Related Experiment Video
Updated: Jan 23, 2026
Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis
Published on: June 10, 2022
Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids
Kevin G Chen1, Pingyu Zhong2, Wei Zheng3
1NIH Stem Cell Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA; Department of Microbiology and Immunology, Georgetown University Medical Center, Washington DC, 20057, USA.
Abstract:
Cystic fibrosis (CF) is a life-shortening genetic disease caused by mutations of CFTR, the gene encoding cystic fibrosis transmembrane conductance regulator. Despite considerable progress in CF therapies, targeting specific CFTR genotypes based on small molecules has been hindered because of the substantial genetic heterogeneity of CFTR mutations in patients with CF, which is difficult to assess by animal models in vivo. There are broadly four classes (e.g., II, III, and IV) of CF genotypes that differentially respond to current CF drugs (e.g., VX-770 and VX-809). In this review, we shed light on the pharmacogenomics of diverse CFTR mutations and the emerging role of stem cell-based organoids in predicting the CF drug response. We discuss mechanisms that underlie differential CF drug responses both in organoid-based assays and in CF clinical trials, thereby facilitating the precision design of safer and more effective therapies for individual patients with CF.
Insights
Stem cell-based organoids can predict cystic fibrosis drug responses for diverse CFTR mutations. This approach aids in developing personalized therapies for cystic fibrosis (CF) patients.
Area of Science:
- Genetics
- Pharmacogenomics
- Regenerative Medicine
Background:
- Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations.
- Current CF therapies show variable efficacy due to CFTR mutation heterogeneity.
- Animal models struggle to accurately predict drug responses across diverse CF genotypes.
Purpose of the Study:
- To review the pharmacogenomics of CFTR mutations.
- To highlight the utility of stem cell-derived organoids in predicting CF drug responses.
- To facilitate precision medicine for individual CF patients.
Main Methods:
- Review of existing literature on CFTR mutation pharmacogenomics.
- Analysis of stem cell-based organoid models for drug screening.
- Discussion of mechanisms underlying differential drug responses in organoids and clinical trials.
Main Results:
- CFTR mutation class influences response to CFTR modulators.
- Organoid-based assays demonstrate genotype-specific drug responses.
- Mechanisms of differential drug response are elucidated through organoid and clinical data.
Conclusions:
- Stem cell-derived organoids are a promising tool for predicting CF drug response.
- Pharmacogenomic insights combined with organoid models enable personalized CF therapy design.
- This approach can lead to safer and more effective treatments for individual CF patients.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
02:30Histone Variants at the Centromere
01:33Adult Stem Cells
00:58Embryonic Stem Cells
00:57Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...